Dr. Mashid is excellent. She is very thorough and actually listens to her patient's concerns and answers questions. Would definitely recommend.
— Susan Crevoisier
Cystoid Macular Edema: Causes, Symptoms, and Treatment
Who Is at Risk
CME can affect a wide range of patients, but certain health conditions, personal characteristics, and surgical factors raise the likelihood of developing it. Knowing your risk can help you and your retina specialist plan ahead and monitor for early signs.
CME is one of the most common complications following cataract surgery. Large-scale data suggest that clinically significant CME is diagnosed in less than one percent of cataract cases, though detailed imaging studies indicate that a much higher percentage of patients develop some degree of macular fluid that may resolve on its own without affecting vision. While the percentage seems small, it still represents a meaningful number of patients each year given how frequently cataract surgery is performed.
Several health conditions and personal characteristics increase the risk of developing CME. Patients with any of the following should discuss their risk with a retina specialist before and after eye surgery.
- Diabetes, which substantially increases the relative risk of CME
- Uveitis, which is associated with CME in a significant portion of affected patients
- Retinitis pigmentosa, which carries a notably elevated risk
- Pre-existing retinal conditions such as diabetic retinopathy, retinal vein occlusion, epiretinal membrane, or macular degeneration
- Younger age, particularly patients under 65
- Male sex
Complex cataract surgery, combined surgical procedures, and surgical complications all increase the risk of CME developing afterward. If a patient has had CME in one eye following cataract surgery, the other eye is also at elevated risk if a similar procedure is performed.
Certain medications can contribute as well. Prostaglandin analog eye drops, commonly used for glaucoma management, have been associated with macular edema in some patients. Smoking is another modifiable risk factor, and reducing or eliminating it may help lower overall risk.
Recognizing the Symptoms
The symptoms of CME most commonly affect the center of the visual field, where sharp detail is processed. Because these symptoms can be mild at first, it is important to have any new or changing vision problems evaluated promptly.
The most common symptom is blurred central vision. Tasks that rely on fine detail, such as reading, using a smartphone, or recognizing faces, may become noticeably harder. Some patients experience metamorphopsia, a condition in which straight lines appear wavy or bent. Colors may look washed out, objects may appear dimmer than usual, and some people notice a pinkish tint or a dark spot in the center of their vision.
In cases related to cataract surgery, symptoms usually develop between one and three months after the procedure, with an average onset of around six weeks. However, CME can appear earlier or later than this window. For CME caused by diabetes, uveitis, or retinal vein occlusion, the timing depends on the severity and activity of the underlying condition, and the onset may be more gradual.
Some visual symptoms are not typical of CME and may signal a more serious emergency. Sudden vision loss in one eye, a curtain or shadow moving across the visual field, a sudden large increase in floaters, or flashes of light should be evaluated immediately. These can be signs of a retinal detachment or other urgent retinal condition that requires emergency care. Do not wait to seek evaluation if these symptoms occur.
How CME Is Diagnosed
Diagnosing CME requires specialized imaging to confirm the presence and extent of fluid in the macula. Our retina specialists use advanced diagnostic technology to evaluate the retina in detail and guide treatment decisions.
Optical coherence tomography, commonly called OCT, is the primary tool used to diagnose CME. This noninvasive imaging test uses light waves to create detailed cross-sectional images of the retina. It reveals the cyst-like fluid pockets within the macular layers and measures retinal thickness with great precision. The test takes only a few minutes, requires no injections, and does not involve any contact with the eye. OCT is also used throughout treatment to track how the macula responds over time.
Fluorescein angiography is an imaging test in which a dye is injected into a vein in the arm. As the dye travels through retinal blood vessels, a specialized camera captures images that show areas of leakage. In CME, the dye accumulates in a characteristic petal-shaped pattern around the fovea. Indocyanine green (ICG) angiography is a similar technique that provides additional detail about deeper vascular layers. These tests can help identify the source and extent of leakage and uncover other vascular contributors to the swelling.
A full dilated eye examination is an essential part of diagnosing CME. It allows the retina specialist to assess overall retinal health and identify underlying conditions that may be driving the edema. In cases where CME follows cataract surgery, the specialist will also look for contributing surgical factors, such as retained lens material, a dislocated intraocular lens implant, or vitreous traction pulling on the macula.
Treatment Options for CME
Treatment for cystoid macular edema is chosen based on its cause, severity, and how the patient has responded to previous therapy. Many cases improve significantly with the right approach, and our retina specialists work closely with each patient to find the most effective plan.
First-line treatment typically involves prescription eye drops. Nonsteroidal anti-inflammatory drug (NSAID) drops reduce the production of prostaglandins, the inflammatory chemicals that drive fluid leakage. These are often combined with corticosteroid drops, which broadly suppress inflammation within the eye. This combination is effective for many patients, especially those with post-surgical CME. Drops are generally used for several weeks to months depending on how quickly the fluid resolves.
When eye drops are not sufficient, intravitreal injections (medication delivered directly into the vitreous gel of the eye) may be recommended. Anti-VEGF agents block vascular endothelial growth factor, a protein that promotes leakage from abnormal or unstable blood vessels. Several FDA-approved anti-VEGF medications are used for this purpose, and they are given on a schedule determined by the patient's response. The procedure is performed with numbing medication and is generally well tolerated.
Steroid injections or slow-release implants placed inside the eye are another treatment option, particularly when inflammation is a significant driver of the edema. A biodegradable dexamethasone implant slowly releases steroid medication over several months and is FDA-approved for macular edema related to retinal vein occlusion and uveitis. Steroid treatments can be effective but do carry risks, including elevated eye pressure and acceleration of cataract formation. A retina specialist will carefully weigh these considerations before recommending this approach.
When CME is caused by an underlying condition such as diabetes, uveitis, or retinal vein occlusion, managing that condition is a core part of treatment. Better blood sugar control in diabetic patients, effective anti-inflammatory therapy for uveitis, and appropriate management of vein occlusion can all help resolve active macular edema and reduce the likelihood of recurrence. In patients with uveitis undergoing eye surgery, perioperative oral corticosteroids have been shown to substantially reduce the risk of post-surgical CME. Our retina specialists coordinate care with other physicians when needed to address these systemic factors.
Faricimab (Vabysmo) is a newer bispecific antibody that targets both VEGF and angiopoietin-2, two proteins involved in vascular leakage and instability. It can be given at intervals ranging from four to sixteen weeks depending on the patient's response, and it has shown promise for refractory CME cases. Retina specialists stay current with evolving treatment options and will discuss emerging therapies when they may be appropriate for a patient's specific situation.
What to Expect During and After Treatment
Recovery from CME varies depending on the cause, severity, and how quickly treatment is started. Most patients see meaningful improvement with appropriate care, though the timeline differs from person to person.
Many patients with CME respond well to treatment. Success rates for resolving the fluid have been reported in the range of 80 to 90 percent with appropriate therapy. Mild post-surgical CME often improves within a few weeks to months, and some cases clear without any treatment at all. More persistent cases may require multiple treatment approaches before the fluid fully resolves. Starting treatment promptly after symptoms appear gives the best chance of a good outcome.
Regular follow-up appointments are essential during and after treatment. OCT scans are used at each visit to measure the amount of fluid remaining in the macula and track changes in retinal thickness. These scans help the retina specialist determine whether treatment is working and whether any adjustments are needed. Even after fluid resolves, monitoring continues for several months, since CME can recur. Patients who have had CME in one eye should also be monitored closely before and after any planned surgery on the fellow eye.
The long-term outlook for CME depends on the underlying cause, how long the edema was present, and how quickly treatment was started. Most patients with post-surgical CME recover good vision with treatment. However, chronic CME that remains untreated for an extended period can damage the photoreceptor cells of the macula, leading to permanent changes in central vision. Early detection and prompt intervention are the most effective ways to protect long-term visual function.
Living With Cystoid Macular Edema
Managing daily life with CME is a challenge for many patients. With the right support and self-care habits, most people can continue their routines while treatment takes effect.
During active CME, central vision tasks such as reading or driving may be harder than usual. Brighter lighting, magnifying aids, and larger font sizes can make reading easier. Driving may need to be limited if central vision is significantly impaired, and a retina specialist can help you understand which activities are safe based on your current level of vision. As treatment reduces the fluid and swelling, vision typically improves gradually.
Following your retina specialist's instructions consistently is one of the most important things you can do during treatment. There are several additional steps that may support your recovery and reduce the risk of recurrence.
- Use all prescribed eye drops exactly as directed and do not stop early
- Attend every scheduled follow-up appointment so imaging can track your progress
- Manage underlying conditions such as diabetes or high blood pressure carefully
- Avoid smoking, which is associated with a higher risk of macular disease
- Report any new or worsening visual changes to your retina specialist promptly
Staying engaged with your care and communicating openly with your retina specialist gives you the best chance of a smooth recovery.
When to See a Retina Specialist
Knowing when to reach out for a retinal evaluation can make a significant difference in your outcome. CME that is caught and treated early is much less likely to cause lasting damage than CME that goes unaddressed for weeks or months.
If you notice blurred or distorted central vision in the weeks or months following cataract surgery, contact a retina specialist as soon as possible. Even if your initial recovery seemed to go smoothly, CME can develop weeks later and may not be obvious until vision is noticeably affected. Early OCT imaging can detect fluid before significant cell damage occurs.
Patients with diabetes, uveitis, retinal vein occlusion, or retinitis pigmentosa should be especially vigilant about retinal monitoring. Regular examinations by a retina specialist can identify early signs of macular edema before symptoms become noticeable. If you have previously had CME in one eye, make sure to mention this to your surgeon before any planned eye procedure on the other eye so preventive measures can be considered.
If your vision does not improve with initial treatment, or if symptoms return after a period of improvement, a retina specialist can reassess your condition and revise your treatment plan. Refractory CME may require a different medication class, a combination approach, or additional evaluation to identify contributing factors that have not yet been addressed.
Frequently Asked Questions
These answers address common questions patients have about CME that go beyond what is covered in the sections above, including guidance on decision-making and when to act quickly.
Mild cases, particularly those that develop after uncomplicated cataract surgery, can sometimes resolve without formal treatment. However, this tends to apply to subclinical edema that does not significantly affect vision. If your vision is meaningfully blurred or distorted, waiting without evaluation is not advisable, because prolonged fluid in the macula can damage the cells responsible for your sharpest sight. Even if the edema does eventually clear on its own, getting examined quickly helps establish a baseline and allows treatment to begin if the fluid is not resolving on a reasonable timeline.
These two conditions are related but not identical. Diabetic macular edema (DME) is specifically caused by diabetes-related damage to retinal blood vessels, and it can appear in a cystoid pattern on OCT imaging. Cystoid macular edema is a broader descriptive term that refers to cyst-like fluid accumulation in the macula from any cause, not only diabetes. While the treatments for DME and CME from other causes often overlap, the underlying condition driving the edema influences which approach is most appropriate, which is why identifying the root cause matters so much.
Not necessarily. Many patients with CME, especially post-surgical cases, respond well to prescription eye drops alone. Intravitreal injections are typically considered when drops have not produced adequate improvement or when the underlying cause, such as retinal vein occlusion or chronic uveitis, is known to respond better to injected therapy. The procedure is performed with topical numbing drops, and most patients describe feeling mild pressure but not significant pain. Your retina specialist will discuss the options clearly and will not recommend injections unless the potential benefit outweighs the risks for your specific situation.
Yes, recurrence is possible, especially in patients whose underlying condition, such as diabetes or uveitis, remains active. After fluid resolves, your retina specialist will continue periodic OCT monitoring to catch any early return of edema before it significantly impacts vision. Staying consistent with prescribed medications and managing systemic conditions carefully are the most effective ways to reduce recurrence risk. If you have had CME once, your eye is also more vulnerable to it developing again following future eye procedures.
The duration varies widely depending on severity and cause. Mild post-surgical CME treated with drops often clears within four to twelve weeks. Cases requiring intravitreal injections may need several months of treatment. CME associated with chronic conditions such as uveitis or diabetes may require ongoing management rather than a fixed treatment course. Your retina specialist will adjust the plan based on how your macula responds at each follow-up visit, so regular attendance at those appointments is essential to keeping treatment on track.
OCT is the primary imaging tool used throughout your follow-up care. It measures retinal thickness and shows whether fluid is decreasing, stable, or returning, all without any needles or dye. In some cases, fluorescein angiography may be repeated if the source of leakage is unclear or if the edema is not responding as expected. The frequency of imaging depends on how actively your condition is being treated and how well your macula is responding. Most patients have OCT performed at every retina visit during active treatment.
Expert Retina Care in Northern Virginia
The Eye Center is home to a fellowship-trained visiting retina team with deep expertise in diagnosing and treating cystoid macular edema and the full range of conditions that affect the retina and macula. Our retina clinic, located at our Lansdowne office, is equipped with advanced imaging technology including OCT, fluorescein and ICG angiography, color fundus photography, and B-scan echography, so your care is thorough from the very first visit. Whether you are dealing with new visual symptoms, recovering from cataract surgery, or managing a chronic retinal condition, we are here to provide attentive, expert care at every step. Contact us to schedule a retina evaluation and take an important step toward protecting your vision.